30.84
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$30.69
Aprire:
$30.43
Volume 24 ore:
172.73K
Relative Volume:
0.19
Capitalizzazione di mercato:
$1.60B
Reddito:
$225.21M
Utile/perdita netta:
$-15.70M
Rapporto P/E:
-91.10
EPS:
-0.3386
Flusso di cassa netto:
$-4.78M
1 W Prestazione:
+5.68%
1M Prestazione:
-8.91%
6M Prestazione:
+83.81%
1 anno Prestazione:
+77.27%
Axogen Inc Stock (AXGN) Company Profile
Nome
Axogen Inc
Settore
Industria
Telefono
(386) 462-6817
Indirizzo
13631 PROGRESS BLVD., ALACHUA, FL
Compare AXGN vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
AXGN
Axogen Inc
|
30.85 | 1.59B | 225.21M | -15.70M | -4.78M | -0.3386 |
|
ABT
Abbott Laboratories
|
110.17 | 192.10B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
343.04 | 137.25B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
88.94 | 115.41B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
68.88 | 103.81B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
84.60 | 49.82B | 6.07B | 1.06B | 1.34B | 1.8063 |
Axogen Inc Stock (AXGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-19 | Iniziato | Wells Fargo | Overweight |
| 2025-12-01 | Iniziato | Mizuho | Outperform |
| 2025-03-17 | Iniziato | Lake Street | Buy |
| 2024-07-01 | Iniziato | Raymond James | Outperform |
| 2022-11-11 | Ripresa | Jefferies | Buy |
| 2022-05-09 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2022-03-11 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Iniziato | Guggenheim | Buy |
| 2020-06-16 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-05-07 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2020-04-02 | Downgrade | BTIG Research | Buy → Neutral |
| 2019-08-07 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2019-07-12 | Iniziato | Canaccord Genuity | Buy |
| 2018-03-02 | Reiterato | Lake Street | Buy |
| 2018-01-05 | Ripresa | Cantor Fitzgerald | Overweight |
| 2017-11-30 | Iniziato | Jefferies | Buy |
| 2017-11-21 | Reiterato | Lake Street | Buy |
| 2017-07-31 | Iniziato | Leerink Partners | Outperform |
| 2017-06-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-03-06 | Iniziato | ROTH Capital | Buy |
| 2016-11-22 | Aggiornamento | Lake Street | Hold → Buy |
| 2016-11-07 | Reiterato | Wedbush | Outperform |
| 2016-11-03 | Downgrade | Lake Street | Buy → Hold |
| 2016-08-04 | Reiterato | Wedbush | Outperform |
| 2014-05-14 | Iniziato | Dawson James | Buy |
| 2013-10-31 | Reiterato | Ladenburg Thalmann | Buy |
Mostra tutto
Axogen Inc Borsa (AXGN) Ultime notizie
Axogen at Citizens Life Sciences Conference: Strategic Growth Insights - Investing.com
AxoGen Conference: AVANCE BLA Approval, Debt Paydown Fuel 2026 Growth Target of 18%+ - MarketBeat
Should Axogen’s 2026 Growth Guidance Amid Wider Losses Require Action From Axogen (AXGN) Investors? - simplywall.st
AxoGen at Leerink Conference: Strategic Growth and Market Expansion - Investing.com India
Chipmakers Recap: Is Axogen Inc in a bullish channel2026 Analyst Calls & Accurate Entry/Exit Alerts - baoquankhu1.vn
Royce & Associates LP Purchases New Shares in AxoGen, Inc. $AXGN - MarketBeat
(AXGN) Risk Channels and Responsive Allocation - Stock Traders Daily
AxoGen Touts FDA BLA Win, Targets 18% Growth and Wider Nerve Repair Adoption - National Today
AxoGen Touts FDA BLA Win, Targets 18% Growth and Wider Nerve Repair Adoption at Raymond James Conference - MarketBeat
AxoGen, Inc. $AXGN Shares Acquired by First Eagle Investment Management LLC - MarketBeat
AXGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Roubaix Capital LLC Purchases New Position in AxoGen, Inc. $AXGN - MarketBeat
Axogen (AXGN) CMO granted 23,000 RSUs and adjusts share holdings - Stock Titan
Axogen (AXGN) innovation chief reports stock awards and tax-share withholding - Stock Titan
Axogen (NASDAQ: AXGN) EVP reports RSU vesting and tax share withholding - Stock Titan
AxoGen, Inc. (NASDAQ:AXGN) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Axogen, Inc. Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Axogen, Inc. Rings the Opening Bell - Nasdaq
Why Axogen (AXGN) Is Down 10.1% After Avance FDA Win and 2026 Guidance Shift - simplywall.st
AxoGen Set to Announce Q4 Earnings on February 24 - Intellectia AI
AXGN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Wall Street Zen Downgrades AxoGen (NASDAQ:AXGN) to Buy - MarketBeat
AxoGen, Inc. (AXGN) Stock Analysis: Strong Buy Ratings Signal A 22.88% Upside Potential - DirectorsTalk Interviews
Equity awards and tax share withholding for Axogen (NASDAQ: AXGN) CFO - Stock Titan
Axogen (NASDAQ: AXGN) CEO granted 98,000 RSUs vesting through 2030 - Stock Titan
Axogen (AXGN) Valuation Check After FDA Avance Approval And New 2026 Growth Targets - Sahm
A Look At Axogen (AXGN) Valuation After Recent Share Price Pullback And BLA Expectations - Yahoo Finance
AxoGen Posts Strong Growth and Raises Capital With Offering - The Globe and Mail
Citizens reiterates AxoGen stock rating on strong quarterly revenue By Investing.com - Investing.com Nigeria
AxoGen, Inc. (NASDAQ:AXGN) Q4 2025 Earnings Call Transcript - Insider Monkey
axogen Q4 2025 slides: 21% revenue surge, stock tumbles on costs - Investing.com India
Citizens reiterates AxoGen stock rating on strong quarterly revenue - Investing.com
Axogen Q4: EPS Miss Amid Biologics Transition (NASDAQ:AXGN) - Seeking Alpha
Axogen Inc earnings beat by $0.01, revenue topped estimates - Investing.com Australia
Decoding Axogen Inc (AXGN): A Strategic SWOT Insight - GuruFocus
AxoGen, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
axogen Q4 2025 slides: 21% revenue surge, stock tumbles on costs By Investing.com - Investing.com South Africa
Axogen (AXGN) CFO receives 17,500 RSUs and 17,500 shares, 6,704 withheld for taxes - Stock Titan
Axogen Inc (AXGN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Axogen (AXGN) Q4 2025 Earnings Call Transcript - Nasdaq
HighMark Wealth Management Buys 158,855 Shares of Axogen Stock - The Globe and Mail
Axogen Inc (AXGN) Q4 2025 Earnings Call Highlights: Strong Reven - GuruFocus
Axogen Inc (AXGN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
CEO Moves: Is Axogen Inc a play on infrastructure spendingMarket Trend Review & High Return Stock Watch Alerts - baoquankhu1.vn
AxoGen Q4 2025 Earnings Call Transcript - MarketBeat
Axogen, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:AXGN) 2026-02-24 - Seeking Alpha
AxoGen Q4 Earnings Call Highlights - MarketBeat
AXGN Stock: Citizens Maintains Rating, Raises Price Target to $4 - GuruFocus
AxoGen (NASDAQ:AXGN) Shares Gap Down on Disappointing Earnings - MarketBeat
AXGN: 2025 saw 20% revenue growth, FDA BLA approval, and strong outlook for 2026 with 18%+ growth - TradingView
Earnings call transcript: AxoGen Q4 2025 beats forecasts, stock dips By Investing.com - Investing.com India
Axogen Inc Azioni (AXGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):